IMROZ
In IMROZ, isatuximab added to VRd cut progression by 40% in older patients not having a transplant.
60-month PFS 63.2% vs 45.2% (HR 0.60); MRD-negative CR 55.5% vs 40.9%. Approved September 2024.
- 63.2 vs 45.2 out of 100 alive without the cancer growing at 60 months with Isa-VRd compared with VRd; 18 more per 100.
- Roughly one extra person helped for every 6 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 40 percent lower chance of the event at any given time (hazard ratio 0.6, likely range 0.41 to 0.88).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Newly diagnosed transplant-ineligible myeloma (age ≤80): Isa-VRd vs VRd. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- TrialCEPHEUS
Shares CD38 antibody added to PI-IMiD-dex (quadruplet induction), CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint, Bortezomib, Lenalidomide.
- PersonPaul G. Richardson
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- PersonKenneth C. Anderson
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- TrialPERSEUS
Shares CD38 antibody added to PI-IMiD-dex (quadruplet induction), Bortezomib, Lenalidomide, Multiple myeloma.
- Key paperMAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant
Shares CD38 antibody added to PI-IMiD-dex (quadruplet induction), CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint, Lenalidomide, Multiple myeloma.
- Key paperPERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma
Shares CD38 antibody added to PI-IMiD-dex (quadruplet induction), Bortezomib, Lenalidomide, Multiple myeloma.
- TrialDREAMM-7
Shares Bortezomib, Multiple myeloma.
- TargetCD38
Shares Isatuximab, CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint, Multiple myeloma.